Search

Your search keyword '"Shekouhi, Ramin"' showing total 28 results
Start Over Author "Shekouhi, Ramin" Search Limiters Full Text
28 results on '"Shekouhi, Ramin"'

27. Evaluation of Long-term Oncological Outcomes of Inter-Sphincter Resection Compared with Traditional Abdominoperineal Resection for Treatment of Low Rectal Cancers: A 5-Year Experience

Author

Anaraki, FakhroSadat, Alemrajabi, Mahdi, Shekouhi, Ramin, Sohooli, Maryam, and Sabz, Seyed-Ali

Abstract

Abdominoperineal resection (APR), is considered the gold standard surgical treatment for low rectal cancer. Anus-preserving alternative procedures have been tested to avoid the need for a permanent colostomy. The present study compares the functional and oncological outcomes of the traditional APR methods with inter-sphincteric resection (ISR).

Published
2023
Full Text
View/download PDF

28. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.

Author

Savaliya BP, Shekouhi R, Mubarak F, Manaise HK, Jimenez PB, Kowkabany G, Popp RA, Popp K, and Gabriel E

Subjects
Humans, Hepatitis B diagnosis, Hepatitis B virology, Hepatitis B drug therapy, Risk Factors, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Hepatitis B Surface Antigens blood, Virus Activation drug effects, Hepatitis B virus drug effects, Hepatitis B virus immunology, Hepatitis B virus isolation & purification, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Neoplasms drug therapy
Abstract

This editorial commented on an article in the World Journal of Gastroenterology titled "Risks of Reactivation of Hepatitis B Virus in Oncological Patients Using Tyrosine Kinase-Inhibitors: Case Report and Literature Analysis" by Colapietro et al . In this editorial, we focused on providing a more comprehensive exploration of hepatitis B virus reactivation (HBVr) associated with the usage of tyrosine kinase inhibitors (TKIs). It includes insights into the mechanisms underlying HBV reactivation, the temporal relationship between TKIs and HBV reactivation, and preventive measures. The aim is to understand the need for nucleos(t)ide analogs (NAT) and serial blood tests for early recognition of reactivation and acute liver injury, along with management strategies. TKIs are considered to be an intermediate (1%-10%) of HBVr. Current guidelines stipulate that patients receiving therapy with high or moderate risks of reactivation or recent cancer diagnosis must have at least tested hepatitis B surface antigen, anti-hepatitis B core antigen (HBc), and anti-hepatitis B surface antibody. Anti-HBc screening in highly endemic areas means people with negative tests should be vaccinated against HBV. Nucleoside or nucleotide analogs (NAs) like entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) form the basis of HBV reactivation prophylaxis and treatment during immunosuppression. Conversely, lamivudine, telbivudine, and adefovir are generally discouraged due to their reduced antiviral efficacy and higher risk of fostering drug-resistant viral strains. However, these less effective NAs may still be utilized in cases where ETV, TDF, and TAF are not feasible treatment options., Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article., (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results